Trial Profile
A Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide in Adults With Newly Diagnosed MGMT Promoter-Methylated IDH Wildtype Glioblastoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Acetazolamide (Primary) ; Temozolomide (Primary)
- Indications Astrocytoma; Glioblastoma
- Focus Adverse reactions
- 02 Mar 2023 Planned End Date changed from 1 Oct 2022 to 1 Oct 2026.
- 02 Mar 2023 Planned primary completion date changed from 1 Aug 2022 to 1 Oct 2026.
- 01 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Oct 2022.